Risk factors predict microscopic extranodal tumor deposits in advanced stage III colon cancer patients

被引:4
|
作者
Jhuang, Yi-Han [1 ]
Chou, Yu-Ching [2 ]
Lin, Yu-Chun [3 ]
Hu, Je-Ming [4 ]
Pu, Ta-Wei [5 ]
Chen, Chao-Yang [4 ]
机构
[1] Natl Def Med Ctr, Triserv Gen Hosp, Div Cardiovasc Surg, Taipei 114, Taiwan
[2] Natl Def Med Ctr, Sch Publ Hlth, Taipei 114, Taiwan
[3] Natl Def Med Ctr, Triserv Gen Hosp, Dept Pathol, Taipei 114, Taiwan
[4] Natl Def Med Ctr, Triserv Gen Hosp, Div Colorectal Surg, 325 Chang Gong Rd, Taipei 114, Taiwan
[5] Natl Def Med Ctr, Triserv Gen Hosp, Div Colorectal Surg, Song Shan Branch, Taipei 114, Taiwan
关键词
Colon cancer; Tumor deposits; Lymphovascular invasion; Risk factor; COLORECTAL-CANCER; METASTASES; INVASION; IMPACT;
D O I
10.3748/wjg.v29.i11.1735
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUNDColorectal cancer is a frequent cause of cancer-related mortality in patients with lymph node or distant metastases. Pericolonic tumor deposits (TDs) are considered prognostically distinct from lymph node metastases.AIMTo investigate risk factors for extranodal TDs in stage III colon cancer.METHODSThis was a retrospective cohort study. We selected 155 individuals diagnosed with stage III colon cancer from the database of the Cancer Registry of the Tri-Service General Hospital. The patients were allocated into the groups with/without N1c. Multivariate Cox regression analysis and Kaplan-Meier method were done. The primary outcomes investigate the association between the covariates and extranodal TDs, and prognostic significance of the covariates regarding the survival.RESULTSThere were 136 individuals in the non-N1c group and 19 individuals in the N1c group. Patients with lymphovascular invasion (LVI) had a higher risk of TDs. Overall survival rates of patients with and without LVI were 6.64 years and 8.61 years, respectively (P = 0.027). The N1c patients without LVI had higher overall survival than those who with LVI (7.73 years vs 4.42 years, P = 0.010).CONCLUSIONPatients having stage III colon cancer with LVI have a higher probability of having TDs than those with stage III colon cancer without LVI. Stage III colon cancer patients with TDs and LVI could have poor prognosis and outcome.
引用
收藏
页码:1735 / 1744
页数:10
相关论文
共 50 条
  • [41] Identification of risk factors for stage II colon cancer
    Sawazaki, Sho
    Shiozawa, Manabu
    Numata, Koji
    Numata, Masakatsu
    Godai, Teni
    Yamamoto, Naoto
    Morinaga, Soichiro
    Rino, Yasushi
    Masuda, Munetaka
    Akaike, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [42] Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer
    P Bohanes
    D Yang
    F Loupakis
    M J LaBonte
    A Gerger
    Y Ning
    C Lenz
    F Lenz
    T Wakatsuki
    W Zhang
    L Benhaim
    A El-Khoueiry
    R El-Khoueiry
    H-J Lenz
    The Pharmacogenomics Journal, 2015, 15 : 226 - 234
  • [43] Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer
    Bohanes, P.
    Yang, D.
    Loupakis, F.
    LaBonte, M. J.
    Gerger, A.
    Ning, Y.
    Lenz, C.
    Lenz, F.
    Wakatsuki, T.
    Zhang, W.
    Benhaim, L.
    El-Khoueiry, A.
    El-Khoueiry, R.
    Lenz, H-J
    PHARMACOGENOMICS JOURNAL, 2015, 15 (03): : 226 - 234
  • [44] Age distribution of tumor gene expression in patients with stage II/III colon cancer.
    Hochster, Howard S.
    Lau, Anna
    Turner, Michelle
    Russell, Christy Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [45] Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients
    Stotz, Michael
    Herzog, Sereina A.
    Pichler, Martin
    Smolle, Maria
    Riedl, Jakob
    Rossmann, Christopher
    Bezan, Angelika
    Stoeger, Herbert
    Renner, Wilfried
    Berghold, Andrea
    Gerger, Armin
    ANTICANCER RESEARCH, 2017, 37 (04) : 2011 - 2018
  • [46] Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients
    Kopetz, Scott
    Jiang, Zhi-Qin
    Overman, Michael J.
    Rosenberg, Robert
    Salazar, Ramon
    Tabernero, Josep
    Stork, Lisette
    Li, Ying
    Simon, Iris
    Chang, George J.
    Maru, Dipen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer
    Touchefeu, Yann
    Provost-Dewitte, Marie
    Lecomte, Thierry
    Morel, Alain
    Valo, Isabelle
    Mosnier, Jean-Francois
    Bossard, Celine
    Eugene, Juliette
    Duchalais, Emilie
    Chetritt, Jerome
    Guyetant, Serge
    Bezieau, Stephane
    Senellart, Helene
    Caulet, Morgane
    Cauchin, Estelle
    Matysiak-Budnik, Tamara
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 28 (12) : 1394 - 1399
  • [48] Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer
    Zhao, Zhengyi
    Cai, Shangli
    Wang, Zhijie
    JAMA ONCOLOGY, 2020, 6 (06) : 932 - 932
  • [49] Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer
    Belt, Eric J. Th
    Brosens, Rebecca P. M.
    Delis-van Diemen, Pien M.
    Bril, Herman
    Tijssen, Marianne
    van Essen, Dirk F.
    Heymans, Martijn W.
    Belien, Jeroen A. M.
    Stockmann, Hein B. A. C.
    Meijer, Sybren
    Meijer, Gerrit A.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S682 - S692
  • [50] Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer
    Eric J. Th. Belt
    Rebecca P. M. Brosens
    Pien M. Delis-van Diemen
    Herman Bril
    Marianne Tijssen
    Dirk F. van Essen
    Martijn W. Heymans
    Jeroen A. M. Beliën
    Hein B. A. C. Stockmann
    Sybren Meijer
    Gerrit A. Meijer
    Annals of Surgical Oncology, 2012, 19 : 682 - 692